The dosage and administration of golidocitinib must be strictly prescribed by a physician. Dosing is generally adjusted based on the patient’s disease condition, treatment tolerability, and treatment phase. As a prescription drug, it requires professional medical evaluation prior to use; the dosage must not be altered nor the treatment discontinued without medical advice.
I. Standard Dosage and Administration
1. Standard Dosage
The recommended adult dose is 50 mg orally once daily, taken on an empty stomach (1 hour before or 2 hours after a meal).
Dose adjustment (e.g., reduction to 25 mg or escalation to 100 mg) may be required for some patients, determined by clinical parameters including complete blood count (CBC), hepatic and renal function.
2. Administration Method
Swallow tablets whole; do not crush or chew. If a dose is missed, take it as soon as remembered within 12 hours of the scheduled time; otherwise, skip the missed dose.
II. Dose Adjustment and Precautions
1. Dose Adjustment
Treatment may need to be interrupted or the dose reduced in patients experiencing severe adverse reactions (e.g., hematologic toxicity, hepatic dysfunction).
Caution is advised in patients with hepatic or renal impairment; dose reduction may be necessary for those with moderate to severe hepatic dysfunction.
2. Contraindications and Precautions for Use
Golidocitinib is contraindicated in patients with hypersensitivity to any ingredient of the drug.
The safety profile in pregnant or lactating women and pediatric patients has not been established, requiring rigorous risk-benefit assessment before use.
3. Adverse Effect Monitoring
Common adverse reactions include thrombocytopenia, anemia, nausea, etc. Regular monitoring of CBC, hepatic and renal function is required.
III. Drug-Drug Interactions
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure to golidocitinib, necessitating close monitoring for toxic reactions.
Concomitant use with anticoagulants or nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided due to an elevated bleeding risk.
IV. Medical Guidance
1. Strict Adherence to Medical Prescription
Prior to treatment initiation, relevant examinations (e.g., genetic testing, pathological diagnosis) must be completed to confirm the indication for golidocitinib.
Immediate medical attention is required if symptoms such as fever, bleeding, or jaundice occur during treatment.
2. Follow-Up and Reassessment
Complete blood count and biochemical parameters should be reviewed every 2–4 weeks, with subsequent treatment regimens adjusted based on the results.
Note: The above information is for reference only. The specific treatment regimen shall be formulated by a physician based on the individual patient’s condition.
